ABSTRACT OF THE DISCLOSURE

The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis.

The invention also relates to the use of of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in the repetitic treatment of pathological conditions that can be related to regulation of expression of at least one gene in a cell, e.g., Cyr61 gene.

10

5